Robyn Karnauskas

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential. Dow’s Performance In 2024 The...

The FDA approval of Amgen, Inc’s (NASDAQ: AMGN) biosimilar version of Johnson & Johnson's (NYSE: JNJ) psoriasis treatment, Stelara, for multiple inflammatory diseases sent shares climbing in early trading on Thursday. Amgen has exhibited the ability “to grow mid-cycle assets,...

Gilead Sciences, Inc. (NASDAQ: GILD), which focuses on antiviral drugs, reported below-consensus fourth-quarter earnings per share Monday, sending its shares down.  The Analysts Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on the shares of Gilead and trimmed the...

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharma company focused on treatments for HIV/AIDS, liver disease, cancer, inflammatory and respiratory, and cardiovascular conditions. The Analyst Citigroup analyst Robyn Karnauskas upgraded shares of Gilead Sciences from Neutral to Buy, with a $...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Monday the failure and discontinuation of two trials for angiopoietin2. Between this and rising rivals, Regeneron bears are emerging. The Rating Citigroup analyst Robyn Karnauskas downgraded Regeneron from Buy to Neutral and lowered the price...

Analysts at Citi no longer hold a bullish view on Biogen Inc (NASDAQ: BIIB). The firm's Robyn Karnauskas downgraded Biogen's stock rating from Buy to Neutral with a new $360 price target. A prior bullish stance on Biogen's stock has been in place since early February and was due to strong...

Celgene Corporation (NASDAQ: CELG)’s discontinuation of mongerson for Crohn’s disease is decidedly negative. The stock plunged 8.2 percent in premarket trading. But the extent of justified pessimism depends on prior expectations. UBS had long discounted mongerson’s prospects and,...

Following strong Phase I and II data on Tuesday from three different triple combo regimens for cystic fibrosis, shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rocketed 30 percent Wednesday to $162.07. The stock’s climb to a new all-time high was assisted by a string of analyst...

Citi’s Robyn Karnauskas said the positive early stage cancer study results from bluebird bio Inc (NASDAQ: BLUE) is positive for CAR-T space and B-cell maturation antigen (BMCA) drugs of Juno Therapeutics Inc (NASDAQ: JUNO) and Kite Pharma Inc (NASDAQ: KITE). Chimeric antigen receptors (CARs)...

Citi’s Robyn Karnauskas expressed concern regarding the lack of potential catalysts for Calithera Biosciences Inc (NASDAQ: CALA) in the near term. Furthermore, the cash burn expected over the next 12–18 months is likewise cause for uncertainty. Karnauskas initiated coverage of the...

Citi’s Robyn Karnauskas believes Five Prime Therapeutics Inc (NASDAQ: FPRX) has a trifecta of factors in its favor, including its “hot” immunoncology (I/O) target, a solid partner in Bristol-Myers Squibb Co (NYSE: BMY) and strong platform technology. Karnauskas initiated...

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by more than 12 percent early Monday morning after the company reported encouraging results from its niraparib Phase 3 NOVA clinical trial results. The trial was designed to assess the progression free survival rate among 553 patients...

Citi has initiated coverage of Kadmon Holdings Inc (NYSE: KDMN) at Neutral, while its $12 price target represents a potential return of 20.4 percent over Friday's close. Kadmon is a small-cap company with two major assets in development for cancer, psoriasis, fibrosis and kidney diseases. However,...